Research Article

Noninvasive biodegradable nanoparticles-in-nanofibers single-dose ocular insert: in vitro, ex vivo and in vivo evaluation

Nanomaterials Lab, Center of Material Science (CMS), Zewail City of Science & Technology, 6th of October, Giza 12578, Egypt

Department of Pharmaceutics & Industrial Pharmacy, College of Pharmacy & Drug Manufacturing, Misr University of Science & Technology (MUST), 6th of October, Giza 12566, Egypt

^‡Authors contributed equally

Search for more papers by this author

Isra H Ali^‡

Nanomaterials Lab, Center of Material Science (CMS), Zewail City of Science & Technology, 6th of October, Giza 12578, Egypt

^‡Authors contributed equally

Search for more papers by this author

Ibrahim M El-Sherbiny

*Author for correspondence: Tel.: +202 3854 0407; Fax: +202 3851 7181;

E-mail Address: ielsherbiny@zewailcity.edu.eg

Nanomaterials Lab, Center of Material Science (CMS), Zewail City of Science & Technology, 6th of October, Giza 12578, Egypt

Search for more papers by this author

Published Online:13 Dec 2018https://doi.org/10.2217/nnm-2018-0297

View article

Abstract

Aim: This study involves, for the first time, the development of mucoadhesive biodegradable polymeric-multilayered nanoparticles-in-nanofibers (NPs-in-NFs) matrix as an innovative single-dose noninvasive ocular-insert that could substitute conventional ocular dosage-forms. Materials & methods: Azithromycin-loaded poly(lactic-co-glycolic acid) copolymer/pluronic NPs were developed then incorporated into electrospun polyvinylpyrrolidone NFs, and tested for their efficient treatment of ocular bacterial infection. Results: Release and permeation studies proved the ability of the insert to control drug release over 10 days. Conclusion: The incorporation of NPs into NFs achieved several other benefits like increasing ocular residence and contact time with conjunctival tissue, accurate dose delivery, sustaining drug release with constant rate, reducing frequency of administration, improving bioavailability along with decreasing incidence of visual and systemic side effects.

Keywords:

References

1 Sevillano D. Azithromycin iv pharmacodynamic parameters predicting Streptococcus pneumoniae killing in epithelial lining fluid versus serum: an in vitro pharmacodynamic simulation. J. Antimicrob. Chemother. 57(6), 1128–1133 (2006).
Medline CASGoogle Scholar
2 Retsema J, Fu W. Macrolides: structures and microbial targets. Int. J. Antimicrob. Agents. 18(Suppl. 1), 3–10 (2001).
Google Scholar
3 Imamura Y, Higashiyama Y, Tomono K et al. Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane. Antimicrob. Agents Chemother. 49(4), 1377–1380 (2005).
Medline CASGoogle Scholar
4 Labro MT. Intracellular bioactivity of macrolides. Clin. Microbiol. Infect. 1, S24–S30 (1996).
MedlineGoogle Scholar
5 Cochereau I, Goldschmidt P, Goepogui A et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double-masked clinical trial. Br. J. Ophthalmol. 91(5), 667–672 (2007).
MedlineGoogle Scholar
6 Dandona R, Dandona L. Socioeconomic status and blindness. Br. J. Ophthalmol. 85, 1484–1488 (2001).
Medline CASGoogle Scholar
7 Cao F, Zhang X, Ping Q. New method for ophthalmic delivery of azithromycin by poloxamer/carbopol-based in situ gelling system. Drug Deliv. 17(7), 500–507 (2010).
Medline CASGoogle Scholar
8 Wei G, Xu H, Ding PT, Li SM, Zheng JM. Thermosetting gels with modulated gelation temperature for ophthalmic use: the rheological and gamma scintigraphic studies. J. Control. Rel. 83(1), 65–74 (2002).
Medline CASGoogle Scholar
9 Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 12(3), 348–360 (2010).
Medline CASGoogle Scholar
10 Li X, Zhang Z, Chen H. Development and evaluation of fast forming nano-composite hydrogel for ocular delivery of diclofenac. Int. J. Pharm. 448(1), 96–100 (2013).
Medline CASGoogle Scholar
11 Kamaleddin MA. Nano-ophthalmology: applications and considerations. Nanomedicine 13(4), 1459–1472 (2017).
Medline CASGoogle Scholar
12 Lalu L, Tambe V, Pradhan D et al. Novel nanosystems for the treatment of ocular inflammation: current paradigms and future research directions. J. Control. Rel. 268, 19–39 (2017).
Medline CASGoogle Scholar
13 Gagandeep, Garg T, Malik B, Rath G, Goyal AK. Development and characterization of nano-fiber patch for the treatment of glaucoma. Eur. J. Pharm. Sci. 53(1), 10–16 (2014).
Medline CASGoogle Scholar
14 Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J. Biomater. Sci. Polym. Ed. 17(3), 247–289 (2006).
Medline CASGoogle Scholar
15 Elbaz NM, Khalil IA, Abd-Rabou AA, El-Sherbiny IM. Chitosan-based nano-in-microparticle carriers for enhanced oral delivery and anticancer activity of propolis. Int. J. Biol. Macromol. 92, 254–269 (2016).
Medline CASGoogle Scholar
16 Hefnawy A, Khalil IA, El-Sherbiny IM. Facile development of nanocomplex-in-nanoparticles for enhanced loading and selective delivery of doxorubicin to brain. Nanomedicine (Lond). 12(24), 2737–2761 (2017).
CASGoogle Scholar
17 Sedeky AS, Khalil IA, Hefnawy A, El-Sherbiny IM. Development of core-shell nanocarrier system for augmenting piperine cytotoxic activity against human brain cancer cell line. Eur. J. Pharm. Sci. 118, 103–112 (2018).
Medline CASGoogle Scholar
18 Ali IH, Khalil IA, El-Sherbiny IM. Single-dose electrospun nanoparticles-in-nanofibers wound dressings with enhanced epithelialization, collagen deposition, and granulation properties. ACS Appl. Mater. Interfaces. 8(23), 14453–14469 (2016).
MedlineGoogle Scholar
19 El-Nabarawi MA, Khalil IA, Saad RM. Impact of hydrophilic polymer solubilization on bioavailability enhancement of repaglinide by solid dispersion. Inven. Rapid Pharm Tech. 2016(3), 1–12 (2016).
Google Scholar
20 Jaiswar DR, Jha D, Amin PD. Preparation and characterizations of stable amorphous solid solution of azithromycin by hot melt extrusion. J. Pharm. Investig. 46(7), 655–668 (2016).
CASGoogle Scholar
21 Alvarado HL, Abrego G, Garduño-Ramirez ML, Clares B, Calpena AC, García ML. Design and optimization of oleanolic/ursolic acid-loaded nanoplatforms for ocular anti-inflammatory applications. Nanomedicine 11(3), 521–530 (2015).
Medline CASGoogle Scholar
22 Kamel KM, Khalil IA, Rateb ME, Elgendy H, Elhawary S. Chitosan-coated cinnamon/oregano-loaded solid lipid nanoparticles to augment 5-fluorouracil cytotoxicity for colorectal cancer: extract standardization, nanoparticle optimization, and cytotoxicity evaluation. J. Agric. Food Chem. 65(36), 7966–7981 (2017).
Medline CASGoogle Scholar
23 Zhang Y, Huo M, Zhou J et al. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 12(3), 263–271 (2010).
MedlineGoogle Scholar
24 Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 13(2), 123–133 (2001).
Medline CASGoogle Scholar
25 Abdellatif MM, Khalil IA, Khalil MAF. Sertaconazole nitrate-loaded nanovesicular systems for targeting skin fungal infection: In-vitro, ex-vivo and in-vivo evaluation. Int. J. Pharm. 527(1–2), 1–11 (2017).
Medline CASGoogle Scholar
26 Sharma C, Dinda AK, Mishra NC. Fabrication and characterization of natural origin chitosan-gelatin-alginate composite scaffold by foaming method without using surfactant. J. Appl. Polym. Sci. 127(4), 3228–3241 (2013).
CASGoogle Scholar
27 Vargas EAT, do Vale Baracho NC, de Brito J, de Queiroz AAA. Hyperbranched polyglycerol electrospun nanofibers for wound dressing applications. Acta Biomater. 6(3), 1069–1078 (2010).
Medline CASGoogle Scholar
28 Lu L, Fu R, Li C et al. Silver nanoparticle/chitosan oligosaccharide/poly(vinyl alcohol) nanofibers as wound dressings: a preclinical study. Int. J. Nanomedicine 8, 4131 (2013).
MedlineGoogle Scholar
29 Sreedhara S, Tata N. A novel method for measurement of porosity in nanofiber mat using pycnometer in filtration. J. Eng. Fabr. Fibers. 8(4), 132–137 (2013).
Google Scholar
30 Senthilraja P, Kathiresan K. In vitro cytotoxicity MTT assay in vero, HepG2 and MCF −7 cell lines study of marine yeast. J. Appl. Pharm. Sci. 5(03), 080–084 (2015).
Google Scholar
31 Askari P, Zahedi P, Rezaeian I. Three-layered electrospun PVA/PCL/PVA nanofibrous mats containing tetracycline hydrochloride and phenytoin sodium: a case study on sustained control release, antibacterial, and cell culture properties. J. Appl. Polym. Sci. 133(16), n/a-n/a (2016).
Google Scholar
32 Zhang Y, Huo M, Zhou J, Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput. Methods Programs Biomed. 99(3), 306–314 (2010).
MedlineGoogle Scholar
33 Suvarna SK, Layton C, Bancroft JD. Bancroft's Theory and Practice of Histological Techniques (7th Edition) [Internet]. Elsevier Health Sciences, The Netherlands. www.elsevier.com/books/bancrofts-theory-and-practice-of-histological-techniques-e-book/suvarna/978-0-7020-5032-9.
Google Scholar
34 Ximenes KF, Silva JV, Vasconcelos KFX, Monte FQ. The role of Descemet's membrane in the pathogeny of corneal edema following anterior segment surgery. Rev. Bras. Oftalmol. 73(5), 262–268 (2014).
Google Scholar
35 Gandhi R, Pillai O, Thilagavathi R, Gopalakrishnan B, Kaul CL, Panchagnula R. Characterization of azithromycin hydrates. Eur. J. Pharm. Sci. 16(3), 175–184 (2002).
Medline CASGoogle Scholar
36 Zhang Y, Lam YM. Controlled synthesis and association behavior of graft pluronic in aqueous solutions. J. Colloid Interface Sci. 306(2), 398–404 (2007).
Medline CASGoogle Scholar
37 Yildirim A, Demirel GB, Erdem R, Senturk B, Tekinay T, Bayindir M. Pluronic polymer capped biocompatible mesoporous silica nanocarriers. Chem. Commun. 49(84), 9782 (2013).
Medline CASGoogle Scholar
38 D'Avila Carvalho Erbetta C. Synthesis and characterization of poly(D,L-lactide-co-glycolide) copolymer. J. Biomater. Nanobiotechnol. 03(02), 208–225 (2012).
Google Scholar
39 Andhariya N, Chudasama B, Mehta RV, Upadhyay RV. Biodegradable thermoresponsive polymeric magnetic nanoparticles: a new drug delivery platform for doxorubicin. J. Nanoparticle Res. 13(4), 1677–1688 (2011).
CASGoogle Scholar
40 Desai K, Mallery S, Schwendeman S. Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(dl-lactide-co-glycolide) implants. Eur. J. Pharm. Biopharm. 70(1), 187–198 (2008).
Medline CASGoogle Scholar
41 Borodko Y, Habas SE, Koebel M, Yang P, Frei H, Somorjai GA. Probing the interaction of poly(vinylpyrrolidone) with platinum nanocrystals by UV–Raman and FTIR. J. Phys. Chem. B. 110(46), 23052–23059 (2006).
Medline CASGoogle Scholar
42 Zhao M, Wang L, Liu H, Wang Y, Yang H. Preparation, physicochemical characterization and in vitro dissolution studies of azithromycin-cyclodextrin inclusion complexes. J. Incl. Phenom. Macrocycl. Chem. 85(1–2), 137–149 (2016).
CASGoogle Scholar
43 Hamoudi-Ben Yelles MC, Tran Tan V, Danede F, Willart JF, Siepmann J. PLGA implants: how poloxamer/PEO addition slows down or accelerates polymer degradation and drug release. J. Control. Rel. 253, 19–29 (2017).
Medline CASGoogle Scholar
44 Rinaudo M. Chitin and chitosan: properties and applications. Prog. Polym. Sci. 31(7), 603–632 (2006).
CASGoogle Scholar
45 Chen S-C, Wu Y-C, Mi F-L, Lin Y-H, Yu L-C, Sung H-W. A novel pH-sensitive hydrogel composed of N,O-carboxymethyl chitosan and alginate cross-linked by genipin for protein drug delivery. J. Control. Rel. 96(2), 285–300 (2004).
Medline CASGoogle Scholar
46 Morsi N, Ghorab D, Refai H, Teba H. Ketoroloac tromethamine loaded nanodispersion incorporated into thermosensitive in situ gel for prolonged ocular delivery. Int. J. Pharm. 506(1–2), 57–67 (2016).
Medline CASGoogle Scholar
47 Seyfoddin A, Sherwin T, Patel DV et al. Ex vivo and in vivo evaluation of chitosan coated nanostructured lipid carriers for ocular delivery of acyclovir. Curr. Drug Deliv. 13(6), 923–934 (2016).
Medline CASGoogle Scholar
48 Qaddoumi MG, Gukasyan HJ, Davda J, Labhasetwar V, Kim K-J, Lee VHL. Clathrin and caveolin-1 expression in primary pigmented rabbit conjunctival epithelial cells: role in PLGA nanoparticle endocytosis. Mol. Vis. 9(October), 559–568 (2003).
Medline CASGoogle Scholar
49 Hardarson SH, Sigurdsson HH, Nielsdottir GE, Valgeirsson J, Loftsson T, Stefansson E. Ocular powder: dry topical formulations of timolol are well tolerated in rabbits. J. Ocul. Pharmacol. Ther. 22(5), 340–346 (2006).
Medline CASGoogle Scholar
50 Vijayasekaran S, Chirila TV, Hong Y et al. Poly(I-vinyl-2-pyrrolidinone) hydrogels as vitreous substitutes: histopathological evaluation in the animal eye. J. Biomater. Sci. Polym. Ed. 7(8), 685–696 (1996).
Medline CASGoogle Scholar
51 Trost LW, Kivilcim M, Peyman GA, Aydin E, Kazi AA. The effect of intravitreally injected povidone-iodine on Staphylococcus epidermidis in rabbit eyes. J. Ocul. Pharmacol. Ther. 23(1), 70–77 (2007).
Medline CASGoogle Scholar

Vol. 14, No. 1

Metrics

Downloaded 350 times

History

Received 17 August 2018

Accepted 29 October 2018

Published online 13 December 2018

Published in print January 2019

Information

Keywords

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

Data availability

The raw/processed data required to reproduce these findings cannot be shared at this time as the data also form part of an ongoing study.

PDF download